On October 27, 2025, Swiss pharmaceutical giant Novartis announced its agreement to acquire Avidity Biosciences, a biotechnology firm specializing in precision cardiology, in a deal valued at $12 billion. This acquisition is poised to strengthen Novartis’s position in the cardiovascular sector and further expand its portfolio of cutting-edge therapies aimed at addressing critical, unmet medical needs.
Avidity Biosciences is known for its innovative approach to precision cardiology, focusing on targeted treatments that have the potential to transform the way cardiovascular diseases are treated. By integrating Avidity’s expertise and technologies, Novartis aims to accelerate the development of new therapies for heart-related conditions, a field that continues to see significant advancements and demand for novel solutions.
As part of the transaction, Avidity Biosciences will spin off its early-stage precision cardiology business prior to the deal’s completion, which is expected to occur in the first half of 2026. This move is intended to streamline Avidity’s operations and focus on its core competencies, while allowing Novartis to benefit from the full potential of Avidity’s innovative treatments.
Novartis’s decision to acquire Avidity Biosciences underscores its strategic focus on expanding its footprint in specialized therapeutic areas and building on its strong track record of advancing healthcare solutions. The cardiovascular space, in particular, is an area of high interest, with rising global prevalence of heart disease creating a growing need for more effective and personalized treatments.
This acquisition marks another significant step in Novartis’s ongoing commitment to addressing the needs of patients suffering from complex conditions. By incorporating Avidity’s cutting-edge technologies into its portfolio, Novartis is positioning itself as a leader in precision medicine, ready to deliver transformative therapies that could change the landscape of cardiovascular healthcare.